Impact of pulsatile pulmonary blood flow on cardiopulmonary exercise performance after the Fontan procedureCentral MessagePerspective

Objective: To evaluate the exercise capacity in patients following Fontan–Kreutzer, Fontan–Björk, and total cavopulmonary connection (TCPC). Methods: Patients who performed exercise capacity tests at least once after the Fontan procedure between 1979 and 2007 were included. Patients after Fontan–Björk procedure were divided into 2 groups according to the pulmonary blood flow (PBF) pattern: patients with pulsatile PBF and those without. Peak oxygen uptake (VO2) was measured and percent-predicted VO2 was calculated. Results: A total of 227 patients were nominated. The types of Fontan procedure included Fontan–Kreutzer in 48 (21.1%) patients, Fontan–Björk in 38 (16.7%); 11 (4.8%) with pulsatile PBF and 27 (11.9%) without pulsatile PBF; and TCPC in 141 (62.1%). Median age at the Fontan procedure was 4.5 years (interquartile range, 2.1-8.2 years). A total of 978 cardiopulmonary exercise tests were performed at median follow-up of 17.7 years (interquartile range, 11.3-23.4 years) postoperatively. Analysis using linear mixed-effects models demonstrated that percent-predicted VO2 was greater in patients with pulsatile PBF after Fontan–Björk compared with patients after other types of Fontan procedure (P < .001). The same results were obtained when the longitudinal percent predicted VO2 was performed using only patients with tricuspid atresia and double inlet left ventricle (P < .001). Conclusions: Among long-term survivors after various types of Fontan procedures, patients with pulsatile PBF after the Fontan–Björk procedure demonstrated better exercise performance compared to those after TCPC, those after the Fontan–Kreutzer procedure, and those after the Fontan-Björk procedure with non-pulsatile PBF. The results implicate the importance of pulsatile PBF to maintain the Fontan circulation

Stereotactic body radiotherapy

Stereotactic body radiation therapy (SBRT) consists of the delivery of precise, conformal, hypofractionated, and ablative therapy in a single or a small number of fractions to extracranial regions. Over the last decade, it is rapidly being integrated into mainstream radiation oncology practices. The indications for SBRT continue to grow, as does the technology associated with its delivery. This chapter presents a detailed overview of clinically relevant topics including patient selection and outcomes, and the technological aspects of planning and delivery of SBRT. The tumor streams covered in this chapter are lung, liver, spine, pancreas, renal cell carcinoma, adrenal, prostate, and head and neck. The chapter concludes by highlighting two novel areas, cardiac arrhythmias and pediatric oncology, in which the use of SBRT is emerging